IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Rabbani et al. Applicant(s 08/978.637 Serial No DEC 2 6 2006 Filed November 25, 1997 For: ON OF MATTER **COMPRISING PRIMARY NUCLEIC ACID COMPONENT**

Group Art Unit: 1635

Examiner: J. Schultz

527 Madison Avenue (9th Floor) New York, New York 10022-4304

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted. 12/27/2006 LWONDIN1 00000036 051135

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of Foreign patent documents and other references are also enclosed to comply with 37 C.F.R. §1.97.

The references are as follows:

Enz53(D5)

U.S. Patent Documents

Foreign Patent Documents

Other Documents

- 1. Junker et al., 1995, Gene Therapy 2:639-645
- 2. Sullenberger et al., 1990, Mol. Cell. Biol. 10:6512-6523

Copies of References (1)-(2) are enclosed

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The Information Disclosure Statement submitted herewith is being filed

[] before the mailing date of a first Office Action on the merits

[x] after the mailing date of a first Office Action on the merits. Please charge the fee of \$180 to Deposit Account No. 05-1135. A duplicate of this sheet is enclosed.

[] An International Search Report is enclosed. References cited in the International Search report are asterisked.

Respectfully submitted,

Date: 12/20/06

Cheryl H. Agris, Reg. No. 34,086

P.O. Box 806

Pelham, N.Y. 10803

(914) 712-0093

Customer No. 25538

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

o a collection of information unless it contains a valid OMB control number.

Substitute for form 1449PTO	Complete if Known		
Substitute for form 1445/F 70	Application Number	08/978,637	
INFORMATION DISCLOSURE	Filing Date	Nov.25, 1997	
STATEMENT BY APPLICANT	First Named Inventor	Rabbani	
	Art Unit	1635	
(Use as many sheets as necessary)	Examiner Name	J. Schultz	
Sheet 1 of 1	Attorney Docket Number	Enz53(D5)	

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Junker et al., 1995, Gene Therapy 2:639-645	
		Sullenberger et al., 1990, Mol. Cell. Biol. 10:6512-6523	
<u> </u>			

Examiner	Date	
Signature	Considered	
o.ga.a.		and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.